

Southend-on-Sea Borough Council

**Report of Director of Public Health
to
Southend-on-Sea Health and Wellbeing Board
on
3rd December 2014**

Report prepared by: James Williams
Head of Health Development Director of

Agenda

Item No.

Southend-on-Sea Pharmaceutical Needs Assessment

**People Scrutiny Committee
Executive Councillor- Councillor Ian Gilbert**

A Part 1 Public Agenda Item

1. Purpose of the Report

- 1.1 To present the Southend-on-Sea Pharmaceutical Needs Assessment (PNA).

2. Recommendation

- 2.1 The Health and Wellbeing Board is asked to approve the Southend-on-Sea Pharmaceutical Needs Assessment.**

3. Background

- 3.1 The Health and Social Care Act 2012 transferred the statutory responsibility for the development and updating of Pharmaceutical Needs Assessments (PNAs) from Primary Care Trusts to Health and Wellbeing Boards, with effect from 1st April 2013. The PNA is a document that provides a full and on-going assessment of the need for pharmaceutical services within a specific area. The PNA tells us what pharmaceutical services are currently available and where we are likely to need changes in the future because of demographic or other changes. If someone wants to provide NHS pharmaceutical services, they are required to apply to the NHS to be included on a pharmaceutical list and must prove they are able to meet a pharmaceutical need.
- 3.2 NHS England (the national body responsible for commissioning pharmaceutical services) relies on PNAs to inform decision making, specifically regarding whether existing pharmaceutical services meet local need. The PNA is also used by NHS England to assess applications from applicants who want to deliver pharmaceutical services within the borough.
- 3.3 The Southend-on-Sea Health and Wellbeing Board is required (under the NHS Pharmaceutical Services and Local Pharmaceutical Services Regulations 2013) to:

- Produce a PNA by 1st April 2015
- Publish a revised PNA within three years of publication of their first assessment; and
- Publish a revised PNA as soon as is reasonably practical, if any significant changes to the availability of pharmaceutical services are identified, unless the Health and Wellbeing Board is satisfied that making a revised assessment would be a disproportionate response

3.4 The Southend-on-Sea Health and Wellbeing Board delegated executive authority to the Director of Public Health (DPH), to oversee the development of a new PNA for Southend-on-Sea. The DPH established a steering group with appropriate terms of reference and governance arrangements to oversee the development of the PNA. The steering group comprised representation from all key representative organisations as required by the regulations. These included:

- Local Pharmaceutical Committee
- Local Medical Committee
- NHS England
- Clinical Commissioning Group representative
- Acute Hospital Trust Representative
- Community Trust (SEPT) Representative
- Local citizen representation (Health Watch)
- Representation from Southend Council Departments
- Representatives from other stakeholders

4. Update on the process of the development of the Southend-on-Sea PNA

4.1 The Council undertook a public consultation exercise during the months of April and May 2014. This exercise enabled the needs of local people (in terms of pharmaceutical services) to be identified. Following the public consultation the draft PNA was reviewed by the PNA steering group and amended.

4.2 The PNA was issued to stakeholders on the 31st July 2014 for a 60 day consultation period (as required by regulations). This statutory consultation period ended on the 6th of October 2014.

4.3 The PNA steering group reviewed all responses received following the 60 day consultation period on the 6th of November 2014. All pertinent issues related to local pharmaceutical services were either:

- accepted comments and updated the PNA, as the responses added value and clarification
- accepted comments but did not update the PNA, as the issue may have been raised by others or were deemed not to add value or clarification

- noted comments but rejected, as the comments were out of scope of the PNA, did not take account of account regulatory requirements, or did not add value to the PNA
- 4.4 Following this final consultation process, the draft Southend-on-Sea PNA was amended and updated as required by regulation, taking into account the criteria described at 4.3.

5. Reason for Recommendation

From 1st April 2013, Health and Wellbeing Boards have assumed the responsibility for the development and publication of local pharmaceutical needs assessments, formerly published by Primary Care Trusts.

6. Corporate Implications

- 6.1 **Contribution to Council's Vision & Corporate Priorities**
Pharmacies are an important part of the healthcare system and play a further role in meeting the health needs of the population by improving public health in a number of areas such as smoking, cardiovascular disease, sexual health and substance misuse.
- 6.2 **Financial Implications**
The cost of the development of the Southend PNA has been met from the public health budget. Any future amendments or revisions of the PNA will also be met by the public health ring-fenced grant and included in future commissioning intentions.
- 6.3 **Legal Implications**
The relevant statutory framework is referred to in Section 3 of this report.
- 6.4 **People Implications**
None.
- 6.5 **Property Implications**
None.
- 6.6 **Consultation**
A public consultation process has been undertaken and a wider stakeholder engagement was undertaken for 60 days and finished on the 6th of October 2014. The PNA was reviewed by the People Scrutiny Committee on the 14th of October 2014. All specified persons and agencies have been provided with the draft PNA as required by the regulations. Summary consultation responses are included in the PNA Section 4.
- 6.7 **Equalities and Diversity Implications**
Equality and diversity issues have been reviewed following the public consultation and have been taken into account in the final version of the PNA.
- 6.8 **Risk Assessment**
The follow key risks were identified as part of the PNA process these were:

- Following a fair unbiased process
- Have regard to the relevant information
- Include the required information
- Consult
- Keep the PNA under review

Appropriate mitigation for these key risks was put in place by the PNA Steering Group. The Director of Public Health will ensure any future versions or amendments to the PNA are carried out in line with the regulatory requirements.

6.9 Value for Money

The PNA development and consultation process has been undertaken within the agreed allocated budget.

6.10 Environmental Impact

Any environmental impacts would be related to the capital developments and subject to specific environmental impact assessment by the regulatory authorities.

7.0 Appendices

7.1 Appendix 1 Final Draft Southend-on-Sea Pharmaceutical Needs Assessment